Pfizer Inc said on Monday it has filed a second lawsuit against Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of anticompetitive conduct. ...

Group 1 - The third quarter earnings season is currently underway, with several AI companies such as Palantir, AMD, and Supermicro reporting their results this week [1][4] - As of October 31, 64% of S&P 500 companies have reported their earnings, with analysts projecting a 10.7% increase in earnings per share for the third quarter, indicating a continuation of double-digit earnings growth for the fourth consecutive quarter, although this represents a slowdown from the 12% growth seen in Q2 [2] - Analysts had initially set lower expectations, forecasting a 7.9% increase in earnings per share for S&P 500 companies prior to the quarter [3] Group 2 - Notable companies expected to report results this week include Shopify, Uber, Pfizer, Spotify, Marriott International, Toyota, Novo Nordisk, McDonald's, AppLovin, Robinhood, DoorDash, Snap, AstraZeneca, ConocoPhillips, Airbnb, Warner Bros. Discovery, Block, Duke Energy, and Wendy's [5]

Clinical Trial Updates - Phase 3 SENTRY试验的顶线数据预计在2026年3月公布[8, 25] - Phase 3 XPORT-EC-042子宫内膜癌试验的顶线数据预计在2026年中期公布[8, 67] - 评估SPd治疗复发性多发性骨髓瘤患者的3期全球研究(XPORT-MM-031/EMN29)的顶线数据预计在2026年上半年公布[70, 73] - SENTRY (XPORT-MF-034) 是一项针对JAKi初治骨髓纤维化患者，Selinexor联合Ruxolitinib的3期试验，已于2025年9月完成患者招募，共353名患者[23, 24] Commercial Performance - 2025年第三季度，美国XPOVIO净产品收入为3200万美元，比2024年第三季度的2950万美元增长8.5%[37] - 公司重申2025年全年净产品收入指导范围为1.1亿美元至1.2亿美元[37, 54] - 社区环境持续驱动约60%的美国整体净产品收入[37] Financial Highlights - 2025年第三季度总收入为4400万美元，高于2024年第三季度的3880万美元[51] - 预计现有流动资金，在计入2025年10月8日宣布的融资交易的影响后，足以支持公司计划运营至2026年第二季度[53] - 研发和SG&A费用预计为2.35亿美元至2.45亿美元[54] Myelofibrosis Market Opportunity - Selinexor联合Ruxolitinib疗法在美国市场可能达到每年约10亿美元的净销售额峰值[41, 43] - 约75%的患者有意愿接受联合治疗[42]

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of ...

Financial Performance - Total net product revenue reached $171.0 million, a 63% year-over-year increase[12, 27] - AUVELITY net product sales were $136.1 million, representing a 69% year-over-year growth[12, 27, 46] - SUNOSI net product revenue amounted to $32.8 million, a 35% year-over-year increase[12, 27, 56] - SYMBRAVO net product sales were $2.1 million[12, 27] - Cash and cash equivalents stood at $325.3 million as of September 30, 2025[12] Pipeline Development & Regulatory Milestones - An sNDA for AXS-05 in Alzheimer's disease agitation has been submitted to the FDA[12, 25, 74] - An NDA submission for AXS-12 for cataplexy in narcolepsy is anticipated in 4Q 2025[12, 25, 109] - A Phase 3 trial of solriamfetol in children and adolescents with ADHD is anticipated in 4Q 2025[12, 25, 82] Strategic Focus & Market Potential - The company is targeting therapeutic areas with high unmet needs, with potential approvals through 2028[11] - The company estimates a combined peak sales potential of >$16 billion across its pipeline[21]

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10, 202 ...

Key Points Novo Nordisk has several catalysts that could jolt its sluggish stock over the next few years. Regeneron is handling biosimilar competition well while mitigating the threat with new launches. 10 stocks we like better than Novo Nordisk › What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced setbacks but before they make a strong comeback is a great way t ...

Market Overview - November begins with stock futures higher, following a successful October driven by artificial intelligence momentum [1] - The S&P 500 rose 2.3%, Dow Jones Industrial Average increased by 2.5%, and Nasdaq Composite jumped 4.7% in October [4] Berkshire Hathaway - Berkshire Hathaway's cash reserves reached a record high of $381.6 billion, surpassing the previous record of $347.7 billion [2] - The company reported a 34% increase in operating profit to $13.485 billion in Q3, with overall earnings rising 17% year over year to $30.8 billion [3] Big Tech Earnings - Major tech companies, including Meta, Amazon, Alphabet, and Microsoft, reported strong digital advertising sales, indicating resilience in ad budgets despite economic uncertainty [4] - The collective capital expenditure for the four tech giants is expected to exceed $380 billion this year, reflecting ongoing investment in AI [5] SNAP Benefits - A federal judge mandated that the Trump administration must utilize emergency funds to continue SNAP food benefits during the government shutdown, affecting 42 million Americans [6][7] Pharmaceutical Market - Eli Lilly and Novo Nordisk dominate the weight loss and diabetes drug market, which could reach $100 billion by 2030 [10] - Both companies are focusing on increasing supply and convenience while testing new uses for their drugs to fend off competition [11]

Key Points A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company. Vertex Pharmaceuticals is rapidly expanding its portfolio in the rare-disease drug market, and growing its profits in the process. 10 stocks we like better than Pfizer › The healthcare industry revolves around constant innovat ...

Getty Images Listen below or on the go via Apple Podcasts and Spotify The director for the Center for Drug Evaluation and Research was accused of making false statements about a drug and soliciting a bribe. (0:15) Baidu’s Apollo Go hits driverless ride landmark. (1:20) Trump says only U.S. will get access to Nvidia’s Blackwell line. (2:08) The following is an abridged transcript: George Tidmarsh is out as director of the FDA’s Center for Drug Evaluation and Research amid accusations that he made fal ...